Kappa Free Light Chain Index Distinguishes MS From Clinical Mimics

Refining the Differential Diagnosis of Inflammatory Demyelination

Establishing an accurate diagnosis in patients presenting with inflammatory demyelinating syndromes remains a significant clinical challenge, as multiple sclerosis often mimics other neuroinflammatory conditions [1]. While the detection of cerebrospinal fluid restricted oligoclonal bands has long served as the gold standard for identifying intrathecal immunoglobulin synthesis, the test is qualitative and subject to rater interpretation [2]. Recent updates to diagnostic criteria have emphasized the need for more objective biomarkers to confirm central nervous system inflammation and predict disease progression [3]. The kappa free light chain index, a quantitative measure of immunoglobulin subunits produced during the immune response, has emerged as a potential alternative with diagnostic sensitivity and specificity comparable to traditional methods [4, 5]. A new multicenter study now provides evidence on how this biomarker performs when specifically tasked with distinguishing multiple sclerosis from its most common clinical mimics, offering clinicians a more standardized tool to guide early treatment decisions.

Multicenter Analysis of Demyelinating Subtypes

The researchers conducted a retrospective case-control study to evaluate the diagnostic utility of the kappa free light chain index across a broad clinical landscape. This multicenter investigation utilized data from 18 French centers through the national NOMADMUS database, a specialized registry for neuromyelitis optica and related neuroinflammatory conditions. The study population comprised 303 total patients, providing a robust sample for comparing biomarker profiles across different demyelinating pathologies. This cohort was divided into three distinct diagnostic groups: 140 patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), 37 patients with aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD), and 126 patients with multiple sclerosis. The demographic data revealed distinct clinical profiles for each group, which helps establish the pretest probability in everyday practice. In the MOGAD group, the median age was 38 years and the sex ratio of females to males was 1:1. The AQP4-NMOSD group showed a much higher female predominance with a sex ratio of 5:1 and a median age of 52 years, representing the oldest cohort in the study. Patients in the multiple sclerosis group presented at the youngest median age of 32 years and exhibited a sex ratio of 4:1. These baseline characteristics align with known epidemiological patterns and establish the framework for assessing how the kappa free light chain index distinguishes multiple sclerosis from conditions that require vastly different immunosuppressive strategies.

Quantifying Intrathecal Synthesis Across Disease States

The kappa free light chain index (KFLC-Index) serves as a quantitative measure of intrathecal immunoglobulin synthesis, reflecting the local production of antibodies within the central nervous system. In this study, the researchers observed a clear gradient in these values across the three diagnostic categories, mirroring different degrees of B-cell activity. The multiple sclerosis group exhibited the highest levels of intrathecal synthesis, with a median KFLC-Index of 49.90 (interquartile range 16.31 to 113.39). This elevated index provides a distinct biochemical signature that aligns with the chronic, compartmentalized immune activation typically seen in multiple sclerosis pathology. In contrast, patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) demonstrated significantly lower evidence of local antibody production. The median KFLC-Index in the MOGAD group was 0.60 (interquartile range 0.33 to 2.09). A critical finding for clinical differentiation was that 71% of patients in the MOGAD group had undetectable levels of cerebrospinal fluid kappa free light chains, suggesting that a complete lack of these proteins strongly points away from multiple sclerosis. The aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder group showed intermediate values, with a median KFLC-Index of 8.85 (interquartile range 3.04 to 16.78). These specific measurements allow clinicians to move beyond qualitative visual assessments of oligoclonal bands and use precise quantitative thresholds to distinguish between these inflammatory demyelinating conditions.

Diagnostic Accuracy and Optimal Thresholds

The researchers evaluated the diagnostic performance of the kappa free light chain index using the area under the curve (AUC), a statistical measure where a value of 1.0 represents a perfect test and 0.5 represents results no better than chance. The KFLC-Index demonstrated high diagnostic accuracy in differentiating MOGAD from multiple sclerosis, yielding an AUC of 0.93 (95% CI 0.9 to 0.96). To assist clinicians in practical application, the study identified an optimal KFLC-Index threshold of 5.7 (95% CI 4.74 to 6.85) for separating these two conditions. This specific cutoff provides a clear numerical benchmark for interpreting cerebrospinal fluid results when the clinical presentation or magnetic resonance imaging findings are ambiguous. At this 5.7 cutoff, the test maintained highly balanced performance metrics. The sensitivity for differentiating MOGAD from multiple sclerosis was 0.89 (95% CI 0.83 to 0.94), meaning the test correctly identified the vast majority of true cases. Similarly, the specificity was 0.89 (95% CI 0.83 to 0.94), representing the test's ability to correctly identify those without the condition. These figures suggest that the KFLC-Index can reliably assist in ruling out multiple sclerosis in patients who actually have MOGAD, thereby reducing the risk of prescribing multiple sclerosis disease-modifying therapies that can inadvertently exacerbate MOGAD. The index also proved useful in other clinical comparisons, though the accuracy levels were slightly lower. For the differentiation of aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder from multiple sclerosis, the KFLC-Index achieved an AUC of 0.82 (95% CI 0.74 to 0.88). Furthermore, the researchers found that the index could help distinguish between the two non-multiple sclerosis conditions, as the KFLC-Index had an AUC of 0.77 (95% CI 0.69 to 0.86) for differentiating MOGAD from neuromyelitis optica spectrum disorder. These data points provide a quantitative framework for clinicians to interpret intrathecal antibody synthesis across the spectrum of inflammatory demyelinating diseases.

Integrating KFLC-Index Into Clinical Practice

The researchers compared the diagnostic utility of the kappa free light chain index (KFLC-Index) against the current gold standard, cerebrospinal fluid restricted oligoclonal bands, which are qualitative markers of intrathecal immunoglobulin synthesis. In the head-to-head analysis, the KFLC-Index did not significantly exceed the diagnostic performance of oligoclonal bands in separating MOGAD from multiple sclerosis. Similarly, when evaluating patients with neuromyelitis optica spectrum disorder, the KFLC-Index did not significantly exceed the diagnostic performance of oligoclonal bands in separating NMOSD from multiple sclerosis. These findings indicate that while the KFLC-Index provides a precise quantitative measurement, it functions as a parallel diagnostic tool rather than a superior alternative to established qualitative assessments. The most significant clinical utility lies in the concurrent use of both biomarkers to reduce diagnostic ambiguity. The study found that the combination of KFLC-Index and oligoclonal bands was more performant than either test used separately, suggesting that integrating both metrics provides a more comprehensive view of the patient's immunological profile. For clinicians, the KFLC-Index offers a valuable supporting criterion to improve the certainty of a differential diagnosis between multiple sclerosis and its mimics, such as MOGAD and AQP4-NMOSD. By utilizing the quantitative precision of the KFLC-Index alongside the qualitative presence of oligoclonal bands, physicians can better navigate the complexities of inflammatory demyelinating diseases, avoid misdiagnosis, and initiate the correct targeted immunotherapy earlier in the disease course.

References

1. Brawerman G, Campos ÂPDF, Pedrosa D, et al. Cerebral metastasis of lung cancer mimicking multiple sclerosis lesions.. Arquivos de Neuro-Psiquiatria. 2024. doi:10.5327/cbn240326

2. Hegen H, Arrambide G, Gnanapavan S, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A consensus statement. Multiple Sclerosis. 2022. doi:10.1177/13524585221134217

3. Menéndez-Valladares P, García‐Sánchez M, Martínez MA, Silva JLGDV, Guitarte CB, Ayuso GI. Validation and meta-analysis of kappa index biomarker in multiple sclerosis diagnosis.. Autoimmunity Reviews. 2019. doi:10.1016/j.autrev.2018.07.010

4. Hegen H, Walde J, Berek K, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis. 2022. doi:10.1177/13524585221134213

5. Tan H, Deng X, ZhangBao J, et al. KFLC-index distinguishes multiple sclerosis from anti-myelin oligodendrocyte glycoprotein and aquaporin 4 diseases in a Chinese cohort. Journal of Neurology Neurosurgery & Psychiatry. 2025. doi:10.1136/jnnp-2025-335953